scholarly journals Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases

1998 ◽  
Vol 57 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Donna Przepiorka ◽  
Sergio Giralt ◽  
Issa Khouri ◽  
Richard Champlin ◽  
Carlos Bueso-Ramos
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Marrow Transplantation ◽  
Myeloproliferative Disorders ◽  
Myelogenous Leukemia ◽  
Allogeneic Marrow Transplantation ◽  
Allogeneic Marrow

scholarly journals Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia

Blood ◽  
1988 ◽  
Vol 71 (4) ◽  
pp. 1144-1146 ◽  
Author(s):  
JE Sanders ◽  
CD Buckner ◽  
ED Thomas ◽  
R Fleischer ◽  
KM Sullivan ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Total Body Irradiation ◽  
Marrow Transplantation ◽  
Family Members ◽  
Myelogenous Leukemia ◽  
Allogeneic Marrow Transplantation ◽  
Total Body ◽  
Allogeneic Marrow

Fourteen children between the ages of 2 and 5 years with juvenile chronic myelogenous leukemia were given cyclophosphamide, total-body irradiation, and marrow transplants. Unmodified marrow was given to six patients who received marrow from HLA-identical siblings and eight patients who received marrow from family members HLA identical for one haplotype but mismatched for one to three loci on the nonshared haplotype. Five patients died of transplant-related complications, and three relapsed at 48, 81, and 1,670 days posttransplant and died of leukemia. Six patients survive in continuous remission from 0.5 to 11.5 years posttransplant.

scholarly journals Allogeneic marrow transplantation for children with juvenile chronic myelogenous leukemia

Blood ◽  
1988 ◽  
Vol 71 (4) ◽  
pp. 1144-1146 ◽  
Author(s):  
JE Sanders ◽  
CD Buckner ◽  
ED Thomas ◽  
R Fleischer ◽  
KM Sullivan ◽  
...  
Keyword(s):  
Chronic Myelogenous Leukemia ◽  
Total Body Irradiation ◽  
Marrow Transplantation ◽  
Family Members ◽  
Myelogenous Leukemia ◽  
Allogeneic Marrow Transplantation ◽  
Total Body ◽  
Allogeneic Marrow

Abstract Fourteen children between the ages of 2 and 5 years with juvenile chronic myelogenous leukemia were given cyclophosphamide, total-body irradiation, and marrow transplants. Unmodified marrow was given to six patients who received marrow from HLA-identical siblings and eight patients who received marrow from family members HLA identical for one haplotype but mismatched for one to three loci on the nonshared haplotype. Five patients died of transplant-related complications, and three relapsed at 48, 81, and 1,670 days posttransplant and died of leukemia. Six patients survive in continuous remission from 0.5 to 11.5 years posttransplant.

Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens.

1993 ◽  
Vol 11 (2) ◽  
pp. 304-313 ◽  
Author(s):  
J P Radich ◽  
J E Sanders ◽  
C D Buckner ◽  
P J Martin ◽  
F B Petersen ◽  
...  
Keyword(s):  
Total Body Irradiation ◽  
Marrow Transplantation ◽  
Acute Gvhd ◽  
High Dose Chemotherapy ◽  
Marrow Transplant ◽  
Myelogenous Leukemia ◽  
High Dose ◽  
Allogeneic Marrow Transplantation ◽  
Total Body ◽  
Allogeneic Marrow

PURPOSE The impact of a second marrow transplant on long-term disease-free survival (DFS) was evaluated for 77 consecutive patients aged 2 to 51 years who relapsed subsequent to allogeneic marrow transplantation after high-dose chemotherapy and total-body irradiation (TBI). PATIENTS AND METHODS Patients received a second transplant for recurrent chronic myelogenous leukemia (CML) (n = 28), acute myelogenous leukemia (AML) (n = 32), and acute lymphoblastic leukemia (ALL) (n = 15) or lymphoma (n = 2) that used the same marrow donor as the initial transplant. High-dose chemotherapy of busulfan (BU) and cyclophosphamide (CY), or CY, carmustine (BCNU), and etoposide (VP-16), was used as a preparative regimen for the second transplant. Graft-versus-host disease (GVHD) prophylaxis consisted of the following: no prophylaxis (n = 8), T-cell depletion (n = 36), methotrexate (MTX) only (n = 21), cyclosporine (CSP) only (n = 1), MTX and CSP (n = 9), or anti-thymocyte globulin (ATG) and prednisone (n = 2). RESULTS Engraftment occurred in the 74 assessable patients. Severe veno-occlusive disease (VOD) was the most frequent cause of grades 3 and 4 regimen-related toxicity (RRT); it occurred in 20 patients. The probability of death before day 100 from nonleukemic causes was 36%. The probability of relapse after second transplant was 70%, and the DFS rate was 14% (median DFS, 36 months; range, 22 to 87). The DFS rates for ALL, AML, and CML were 8%, 10%, and 25%, respectively. Multivariate analysis showed that the risk of relapse was inversely associated with acute GVHD (relative risk [RR] of relapse = 0.2; P = .0009). No other factor was associated with relapse. DFS was associated with the presence of acute GVHD (RR of treatment failure = 0.5; P = .0085), and a reduction of DFS was associated with severe VOD (RR = 10.6; P = .0001) and those patients older than 10 years (RR = 2.5; P = .0337). CONCLUSION These data show that some patients may benefit from a second marrow transplant for recurrent leukemia after an initial marrow transplant. Younger patients and patients with CML especially should be considered as potential candidates for a second transplant.

scholarly journals Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation

Blood ◽  
1986 ◽  
Vol 67 (6) ◽  
pp. 1693-1697 ◽  
Author(s):  
J Rajantie ◽  
GE Sale ◽  
HJ Deeg ◽  
D Amos ◽  
F Appelbaum ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Myeloproliferative Disorders ◽  
Allogeneic Bone ◽  
Biopsy Specimens ◽  
Red Blood Cell Transfusions ◽  
Allogeneic Marrow Transplantation ◽  
Allogeneic Marrow ◽  
Marrow Fibrosis ◽  
Severe Fibrosis

Abstract We reviewed the records and marrow biopsy specimens of 75 patients with leukemic, myelodysplastic, or myeloproliferative disorders to determine whether the presence of marrow fibrosis affected engraftment after allogeneic marrow transplantation. While 28 control patients without fibrosis achieved prompt engraftment, two of 32 patients (6%) with mild and five of 15 patients (33%) with severe fibrosis failed. The rate of myeloid recovery was significantly slower and the dependence on platelet and red blood cell transfusions was significantly longer in patients with severe fibrosis than in patients with no fibrosis. A finding of severe marrow fibrosis should therefore be taken into account when evaluating the risks and benefits of marrow transplantation.

scholarly journals Adverse effect of severe marrow fibrosis on hematologic recovery after chemoradiotherapy and allogeneic bone marrow transplantation

Blood ◽  
1986 ◽  
Vol 67 (6) ◽  
pp. 1693-1697 ◽  
Author(s):  
J Rajantie ◽  
GE Sale ◽  
HJ Deeg ◽  
D Amos ◽  
F Appelbaum ◽  
...  
Keyword(s):  
Marrow Transplantation ◽  
Allogeneic Bone Marrow Transplantation ◽  
Myeloproliferative Disorders ◽  
Allogeneic Bone ◽  
Biopsy Specimens ◽  
Red Blood Cell Transfusions ◽  
Allogeneic Marrow Transplantation ◽  
Allogeneic Marrow ◽  
Marrow Fibrosis ◽  
Severe Fibrosis

We reviewed the records and marrow biopsy specimens of 75 patients with leukemic, myelodysplastic, or myeloproliferative disorders to determine whether the presence of marrow fibrosis affected engraftment after allogeneic marrow transplantation. While 28 control patients without fibrosis achieved prompt engraftment, two of 32 patients (6%) with mild and five of 15 patients (33%) with severe fibrosis failed. The rate of myeloid recovery was significantly slower and the dependence on platelet and red blood cell transfusions was significantly longer in patients with severe fibrosis than in patients with no fibrosis. A finding of severe marrow fibrosis should therefore be taken into account when evaluating the risks and benefits of marrow transplantation.

Sign in / Sign up

Export Citation Format

Share Document